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874-3 Assessment of Microvolt T Wave Alternans on and off 
Beta-Blocker Therapy
Pawel Ptaszynski, Thomas Klingenheben, Stefan H. Hohnloser, J.W. Goethe University 
Frankfurt, Frankfurt, Germany
Background: Microvolt level T-wave alternans (MTWA) is increasingly used for arrhythmia
risk stratification in patients prone to malignant ventricular tachyarrhythmias and sudden
cardiac death. Antiadrenergic therapy by means of beta blocker (BB) administration may
influence MTWA assessment using exercise testing, mainly because patients may not
achieve a sufficient increase in heart rate. However the effects of BB on MTWA assess-
ment have not been prospectively studied.
Methods. Consecutive patients scheduled for ICD implantation underwent noninvasive
MTWA assessment using bicycle exercise testing (spectral method; CH2000, Cambridge
Heart Inc) on and off BB treatment in random order. Antiadrenergic therapy was withheld
for at least 5 half lifes prior to the test off BB. Results of MTWA tests were compared
using Fisher’s exact test. Separate analysis was performed in a subgroup of patients who
were on chronic amiodarone treatment. 
Results: Sixty-six patients were included in the protocol. Of these, 17 were treated with
amiodarone. Patients on BB had a resting heart rate of 71+10 bpm compared to 79+10
bpm of BB (p<0.05). The maximal exercise heart rate averaged 102+13 bpm to 107+13
bpm of BB (p<0.05). Whereas 13 pts (27%) tested MTWA positive on BB, the positivity
rate was 47% (23 pts) off the drug (p=0.05).The prevalence of an indeterminate test
result decreased from 41% to 24% (p=0.09). In the subgroup of patients with amio-
darone, no patient tested MTWA positive, irrespective of the status of BB therapy. The
proportion of indeterminate tests was 88% on and 82% off BB therapy exclusively due to
chronotropic incompetence during testing.
Conclusion: MTWA assessment is facilitated by withholding BB prior to testing by reduc-
ing the prevalence of indeterminate tests as a consequence of insufficient heart rate
increase. Chronic amiodarone therapy results in chronotropic incompetence in almost all
patients which precludes exercise-based MTWA assessment.
9:15 a.m.
874-4 Hypertensive Stress Enhances Repolarization 
Heterogeneity
Bart Hooft van Huysduynen, Cees A. Swenne, Henk J. Ritsema van Eck, Anna L. 
Schoneveld, Hedde van de Vooren, Jan A. Kors, Piet Schiereck, Martin J. Schalij, Ernst 
E. van der Wall, Leiden University Medical Center, Leiden, The Netherlands, Erasmus 
University Rotterdam, Rotterdam, The Netherlands
Purpose: Several electrocardiographic indexes for heterogeneity of cardiac repolariza-
tion have been put forward: the QT interval, the QT-dispersion, the Tapex-Tend interval
and singular value decomposition as a measure of the complexity of the T wave. Some
postulate that the duration of longest action potentials are measured in the U wave. We
studied the behavior of these alternative indexes under three different conditions; rest
(R), normotensive gravitational stress (NORM) and hypertensive isometric stress (HYP).
Methods: Fifty-six healthy male volunteers participated. A continuous 12 lead ECG and
blood pressure were recorded during R (sitting with horizontal legs), NORM (sitting with
lowered legs at increasing angles) and HYP (sitting with horizontal legs while performing
a 3-minute handgrip at 30% of the maximal force). In each volunteer a leg-lowering angle
was sought at which the heart rate differed less than 10 % from the heart rate during
handgrip. This succeeded in 41 subjects, who constituted the final study group.
Results: Heart rate increased from 63 ± 9 during R to 71 ± 11 bpm during both NORM
and HYP. Systolic blood pressure was 122 ± 15 in R, remained 121 ± 15 during NORM
and increased to 151 ± 17 mmHg during HYP. QT and QTc were larger during HYP (405
± 27 and 433 ± 17 ms) than during NORM (389 ± 26 and 421 ± 18 ms, P<0.001). QT dis-
persion did not differ significantly between HYP (51 ± 26 ms) and NORM (45 ± 22 ms,
NS). The Tapex-Tend interval in V2 was larger during HYP (125 ± 18 ms) than during
NORM (117 ± 15 ms, P<0.001). The distance between the apices of the T and the U
wave was significantly larger during HYP (191 ± 44 ms) than during NORM (158 ± 36,
P<0.001). Fixed and moving window singular value decomposition indexes were larger
during HYP (0.144 ± 0.071 and 0.075 ± 0.032) than during NORM (0.089 ± 0.053 and
0.048 ± 0.022, P<0.001). 
Conclusion: Most measures put forward as indexes of repolarization heterogeneity were
larger during hypertensive stress than during normotensive stress. Hypertensive stres-
sors, like mental stress, are associated with arrhythmogeneity in vulnerable hearts. Our
study provides one possible explanation for this, because hypertensive stress enhances
repolarization heterogeneity.
9:30 a.m.
874-5 Optimal Prognostication From the 12-Lead ECG: Spatial 
Angle Between the QRS and T Wave Complexes
Takuya Yamazaki, Greg Engel, Clifton Watt, Jonathan Myers, Sung Chun, Victor F. 
Froelicher, VA Palo Alto Health Care System, Stanford University, Palo Alto, CA
Objective: To evaluate the prognostic value of a new criterion that combines measure-
ments from repolarization and depolarization by considering the orientation of the QRS
and T axis.
Methods: Analyses were performed on the first ECG digitally recorded on 46,950 con-
secutive patients at the Palo Alto Veterans Affairs Medical Center since 1987. Females
and patients with paced rhythms, WPW, BBBs, IVCD, LVH, atrial fibrillation and diagnos-
tic Q waves were excluded from all analysis, leaving 31,074 patients with a mean age of
55 years. Using computerized trigonometric algorithms, spatial QRS, T axis and T
lambda (the spatial T-axis deviation from normal reference direction) were synthesized by
deriving XYZ leads from the 12 leads using the inverse Dower weighting matrix and simi-
larly by using the unadjusted amplitudes from leads I, aVF and V2. Spatial QRS-T angle
was categorized into three groups: normal (0 to 50º), borderline (50 to 100º) and abnor-
mal (100 to 180º). The main outcome measure was cardiovascular (CV) mortality. 
Results: During a mean follow-up of 6 years there were 1,878 CV deaths. After adjusting
for age and heart rate in a Cox regression model, spatial QRS-T angle difference was the
most significant predictor of CV mortality, outperforming all other ECG findings including
T wave and QRS amplitude and axis, T lambda, QRS duration, QT interval and disper-
sion and ST depression. Annual mortality was 0.6% for normal, 1.5% for borderline and
4.0% for the abnormal group. The borderline and abnormal groups each had a 34% step-
increase in mortality. Similar results were found when Q waves, RBBB, IVCD, and LVH
were included and considered in the model. The predictive significance remained when I,
aVF and V2 were used to develop the spatial vector angles.
Conclusion: Spatial QRS-T angle is a significant and independent predictor of cardio-
vascular death providing more information than any other established ECG characteris-
tics, and can easily be calculated as part of computerized ECG analysis. 
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875-1 Cardioversion in Patients With Dense Spontaneous 
Echo Contrast
Faisal O. Alatawi, Joseph Malouf, Chandrasekaran Krishnaswarmy, Saeed A. Al Ahmari, 
Brenda S. Moon, Charles J. Bruce, Naser A. Ammash, Mayo Clinic, Rochester, MN
Background:Dense spontaneous echo contrast (SEC) in left atrial appendage is associ-
ated with increased risk of thrombus formation. The risk of thromboembolism (TE) follow-
ing electrical cardioversion is yet to be determined.
Methods: 133 patients (pts) mean age 72 ± 10 years, male 76.7% with non rheumatic
atrial fibrillation (AF) 74%) or atrial flutter (FL) 26%, without mitral valve disease sched-
uled for Transesophageal Echocardiogram guided cardioversion between May 2000 to
May 2003, were noted to have SEC .The SEC was described as less than mild in 75 pts
56.4% ( group 1), severe in 58 pts (44.6%) group 2, The success and complication rates
following cardioversion were analyzed.
Results: both groups were similar with respect to , age, gender, diabetes, hypertension
and rhythm. Univariate comparitive analysis is summarized in the table below. 
CONCLUSION: Dense spontaneous echo contrast in the left atrial appendage with very 
low LAA emptying velocity should not preclude from external biphasic electrical cardio-
version. Dense spontaneous echo contrast carries similar success rate and thromboem-
bolic risk as those with mild or less spontaneous echo contrast and high LAA emptying 
velocity.
8:45 a.m.
875-2 Do Randomized Trials Affect Clinical Practice? AFFIRM, 
RACE, and the Management of Atrial Fibrillation
Pamela K. Mason, Mark A. Wood, Douglas Lake, John P. DiMarco, University of Virginia 
Health System, Charlottesville, VA, Medical College of Virginia, Richmond, VA
The impact of trials on clinical practice is often delayed. In 3/2002, the results of 2 ran-
domized trials (AFFIRM and RACE) comparing rate control and rhythm control strategies
in patients with atrial fibrillation (AF) were presented. Both studies reported no benefit
with a rhythm control strategy with trends favoring a rate control approach. We hypothe-
sized that these data would result in 2 changes in clinical practice: a decrease in elective
cardioversions and an increase in atrioventricular junctional (AVJ) ablations in patients
with AF. At the University of Virginia Health System, Charlottesville, VA and the Medical
College of Virginia, Richmond, VA, we compared the numbers of elective cardioversions
and AVJ ablations performed during the 52 months prior to the release of the AFFIRM
and RACE trial data to the numbers performed during the 14 months after their release.
There was a decrease in cardioversion frequency after the trials were presented.
Between 1/1998 and 3/2002, an average of 31 elective cardioversions were performed
each month, whereas between 4/2002 and 6/2003, 23 cardioversions were performed
covariate Group1 (n=75) Group2 (n=58) P value
AF / FL 53 / 22 46 / 12 0.3
History of TE (n) 1 7 0.009
History of congestive heart failure % 21% 53% 0.0001
LVEF(mean ±SD) 53 1±3 44.5 ±16 0.0008
Left atrial appendage emptying velocity 
(average of peak for 5 cycles) cm/s
46±16
(30 –62)
17±7
(10 – 24)
<0.0001
Successful cardioversion % 97 92 0.19
Post cardioversion thromboembolic 
events(n)
1 0 0.356
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monthly (p = 0.001). In contrast, AVJ ablations increased. During the same time periods,
an average of 6 AVJ ablations were performed each month prior versus a average of 10
after the trial data were presented (p = 0.001).
We conclude that AFFIRM and RACE trial data resulted in an early change in the man-
agement of patients with AF at these 2 institutions with a shift in practice towards a rate
control strategy.
9:00 a.m.
875-3 Suppression of Paroxysmal Atrial Tachyarrhythmias: 
Results of the SOPAT Trial
Monica Patten, Renke Maas, Bernd Lüderitz, Frank Sonntag, R. Hatala, M. Dluzniewski, 
G. Opolski, Thomas Meinertz, University Hospital Hamburg, Eppendorf, Hamburg, 
Germany
SOPAT is a prospective, double-blind, randomized trial to answer the following questions:
1. What is the average rate of spontaneous events of symptomatic atrial fibrillation
(sAF)? 2. Does treatment with sotalol or quinidine + verapamil significantly reduce the
recurrence rate of sAF? 3. How safe are these drugs?
Over 60 months 1033 pts. (mean age 60 yrs, 63% male, 12% heart failure) presenting at
least one episode of sAF one month prior to enrolement were recruted in 171 centres in
Germany, Poland and the Slovak Republic. Pts. were randomized to either 160 mg
sotalol bid (262 pts.), 160 mg quinidine + 80 mg verapamil (Q+V) bid (263 pts.), Q+V tid
(256 pts.) or placebo (252 pts.). Pts. received an ECG recorder (RhythmCard®, Instro-
medix) to record one 1-min ECG daily and in case of symptoms. ECGs were transmitted
by telephone to a central analysis unit together with pts. symptoms. The primary endpoint
was defined as the time to first recurrence of sAF or study discontinuation. Secondary
endpoint was the number of days with AF. During the one year follow-up 296260 Tele-
ECGs were transmitted and analysed.
The mean follow-up period was 233 ± 152 d. Premature study termination was highest in
the placebo group with 59% vs. 41% under Q+V tid, and 42% under Q+V bid and sotalol.
Regarding the primary endpoint all active treatments were superior to placebo and equiv-
alent to each other. A total of 756 pts. reached the primary endpoint within 106 ± 9 d
(mean ± SEM) under placebo, vs. Q+V tid: 150 ± 10 d (p= 0.0061), vs. Q+V bid: 149 ± 11
d (p= 0.0006), vs. Sotalol: 146 ± 9 d (p= 0.0007). Burden of sAF, determined as the rela-
tive number of days with sAF, was significantly reduced in all treatment groups compared
to placebo (mean ± SD: 6.1 ± 13.5)vs. Q+V tid (3.4 ± 12, p=0.0001), Q+V bid (4.5 ± 12.3,
p=0.008), and Sotalol (2.9 ± 6.5, p=0.026). A total of 6 deaths, 18 syncopes, and 1 ven-
tricular tachycardia occurred with a comparable risk profile for all treatment groups.
In conclusion, treatment with Q+V is equivalent to sotalol in reducing the recurrence rate
of symptomatic AF with a low risk of life-threatening events in pts. with lone AF or minimal
structural heart disease.
9:15 a.m.
875-4 The Incidence of Cerebral Embolism After 
Percutaneous Occlusion of the Left Atrial Appendage: A 
Serial and Prospective Study Using Cerebral Magnetic 
Resonance Imaging Scanning
Heyder Omran, Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Stephanie 
Kuntz-Hehner, Thorsten Sommer, Berndt Lüderitz, David Hardung, University of Bonn, 
Bonn, Germany
Background: Percutaneous left atrial appendage (LAA) occlusion has been introduced as
an alternative treatment in patients with atrial fibrillation and increased thromboembolic
risk. However, the long term risk of cerebral embolism under this new treatment is
unknown. The aim of the study was to evaluate the long-term risk of cerebral embolism
by serial cerebral MRI scanning.
Methods: 20 Patients with contraindications to warfarin or bleeding complications under
oral anticoagulation were enrolled in the study. Serial neurological and echocardio-
graphic examinations were undertaken prior to and during the procedure and in addition
at 1 month, 2 months, 6 and 12 months. Cerebral MRI including diffusion weighted
sequences was performed prior to the procedure, 48 hours after and 6 and 12 months
after the procedure to assess for cerebral microembolism.
Results: Cerebral MRI performed prior to the occlusion procedure detected the presence
of former cerebral embolism in 8 out of the 20 patients. Follow-up MRI studies excluded
the presence of new cerebral microembolism in all patients. TTE and TEE examinations
did not reveal de novo thrombus formation in the LA or thrombotic appositions on the sur-
face of the occlusion device.
Conclusions: Long term follow-up of patients with occlusion of the left atrial appendage
did not reveal cerebral thromboembolism on serial cerebral MRI. Percutaneous left atrial
appendage occlusion is an alternative treatment in patients at high risk of thromboembo-
lism and contraindications to oral anticoagulation therapy.
9:30 a.m.
875-5 Randomized Trial of Two Antiarrhythmic Agents 
(Amiodarone and Sotalol) in Patients With Atrial 
Fibrillation for Whom Direct Current Cardioversion Is 
Planned
Kunadian Vijayalakshmi, Michael J. Stewart, James A. Hall, Adrian Davies, Mark A. de 
Belder, The James Cook University Hospital, Middlesbrough, United Kingdom
Anti-arrhythmic agents enhance maintenance of sinus rhythm (SR) following direct cur-
rent cardioversion (DCC) for atrial fibrillation (AF) but there are few comparative trials.
Aims: (1)To establish whether taking amiodarone or sotalol (at standard clinical doses) is
better at achieving chemical cardioversion within the 6 weeks prior to planned DCC. (2)To
establish whether DCC is more likely to be successful on an anti-arrhythmic agent and
(3) to establish whether patients successfully cardioverted to SR are more likely to stay in
SR over 6 months if taking a drug and if so to establish whether one agent is better than
the other.
Methods: Randomised, prospective, non-blinded, controlled study of treatment with
either amiodarone, sotalol or no anti-arrhythmic agent to start 6 weeks prior to DCC, and
treatment to continue for a further 6 months. Patients with time of onset of AF within the
last 1 year were included. 94 patients were enrolled in the study (nil group n=31, sotalol
n=36 and amiodarone n=27). Follow up visits were at 6 weeks and 6 months post DCC.
Results: A total of 7 (25%) patients in the amiodarone group (A), 7 (19%) patients in the
sotalol group (S) were chemically cardioverted to SR, compared to none (0%) in the no
anti-arrhythmic group (N) [p=0.002 (AvN), 0.01 (SvN), 0.5 (AvS) respectively]. A total of
26/29 (90%) patients in the sotalol group were successfully cardioverted to SR compared
to 15/20 (75%) patients in the amiodarone group and 23/31 (74%) patients in the no anti-
arrhythmic group [p=0.03 (SvA), 0.05 (SvN), 0.9 (AvN) respectively]. At 6 month review
17 (62%) patients in the amiodarone group were in SR compared to 14 (38%) patients in
sotalol group and only 5 (16%) patients in the no anti-arrhythmic group [p=0.05 (AvS),
<0.05 (AvN) respectively]. Intention to treat and actually treated analysis gave similar
results.
Conclusion: Treatment with either amiodarone or sotalol for 6 weeks had equal efficacy
in achieving chemical cardioversion before planned DCC. Sotalol significantly increased
the chance of DCC producing SR. After successful cardioversion, amiodarone signifi-
cantly reduced the rate of reversion to AF and increased the chance of being in SR at 6
months
9:45 a.m.
875-6 Early Recurrence of Arrhythmia Is Common in Patients 
Taking Amiodarone or Type IC Agents for Treatment of 
Atrial Fibrillation or Atrial Flutter
Thomas H. Hauser, Duane S. Pinto, Mark E. Josephson, Peter Zimetbaum, Beth Israel 
Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA
Background: Amiodarone use for the prevention of recurrent atrial fibrillation or flutter
requires drug loading over several weeks. The rate of recurrent arrhythmia during amio-
darone loading has not been investigated. We compared the rates of recurrent arrhyth-
mia in patients treated with amiodarone and type IC agents, which do not require drug
loading.
Methods: We prospectively monitored a cohort of patients with ambulatory loop record-
ers during outpatient drug loading after spontaneous or electrical cardioversion to sinus
rhythm.
Results: The study cohort comprised 339 patients who were treated with amiodarone
(212), propafenone (64) or flecainide (63). Patients taking amiodarone were older (74 ±
11 vs. 59 ± 12, p <0.001) and more likely to have left ventricular dysfunction (80 [39%] vs.
8 [7%], p <0.001). Arrhythmia recurred in 106 (31.3%) and was persistent in 44 (13.0%).
The incidence of recurrent arrhythmia at 15 days was much less in patients treated with
amiodarone compared to those treated with a type IC agent (25.4% vs. 42.5%, p <
0.001) (Figure). Persistent arrhythmia was also much less in patients treated with amio-
darone (9.9% vs. 19.2% at 15 days, p = 0.011). Of those with recurrent arrhythmia, 58
(55%) were asymptomatic.
Conclusion: Recurrent arrhythmia is common and frequently asymptomatic during drug
loading with both amiodarone and type IC agents but is usually not persistent. The inci-
dence of recurrent arrhythmia during drug loading is much less with amiodarone com-
pared to type IC agents. 
